SYCREST – A new atypical antipsychotic
Date: 26 Oct 2011

C.G. Papaloisou is introducing SYCREST sublingual tablets (5 mg, 10 mg), a new atypical antipsychotic marketed by H. LUNDBECK A/S.

SYCREST (asenapine) is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Full prescribing information can be found here.